Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Standard Biotools (LAB) Preferred Stock Liabilities (2022 - 2023)

Standard Biotools (LAB) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $311.3 million as the latest value for Q4 2023.

On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $311.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $311.3 million, a 0.0% change, with the full-year FY2023 number at $311.3 million, changed 0.0% from a year prior.
Preferred Stock Liabilities was $311.3 million for Q4 2023 at Standard Biotools, roughly flat from $311.3 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $311.3 million in Q2 2022 to a low of $311.3 million in Q2 2022.